Table 2 Adverse event frequency by type and severity level in the two treatment arms (Gordon et al, 2001; Smith et al, 2002)

From: Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain

Adverse event type

Grade

PLD n (%)

Topotecan n (%)

Anemia

Total

319 (100)

985 (100)

 

Grade I

199 (62)

363 (37)

 

Grade II

101 (32)

476 (48)

 

Grade III

18 (6)

134 (14)

 

Grade IV

1 (0)

12 (1)

Thrombocytopenia

Total

71 (100)

944 (100)

 

Grade I

54 (76)

434 (46)

 

Grade II

14 (20)

272 (29)

 

Grade III

3 (4)

175 (19)

 

Grade IV

0 (0)

63 (7)

Neutropenia

Total

311 (100)

1438 (100)

 

Grade I

153 (48)

296 (20)

 

Grade II

105 (35)

378 (26)

 

Grade III

42 (14)

427 (30)

 

Grade IV

11 (3)

337 (24)

Sepsis

Total

4 (100)

17 (100)

 

Grade I

0 (0)

0 (0)

 

Grade II

1 (25)

5 (35)

 

Grade III

3 (75)

3 (15)

 

Grade IV

0 (0)

9 (50)

Fever

Total

69 (100)

65 (100)

 

Grade I

36 (55)

31 (48)

 

Grade II

26 (42)

20 (31)

 

Grade III

2 (3)

8 (12)

 

Grade IV

0 (0)

5 (9)

Stomatitis/Pharyngitis

Total

378 (100)

130 (100)

 

Grade I

202 (53)

91 (70)

 

Grade II

144 (38)

37 (28)

 

Grade III

31 (8)

2 (2)

 

Grade IV

1 (0)

0 (0)

Nausea/Vomiting

Total

386 (100)

567 (100)

 

Grade I

236 (61)

333 (59)

 

Grade II

110 (28)

175 (31)

 

Grade III

37 (10)

51 (9)

 

Grade IV

3 (1)

8 (1)

Diarrhoea

Total

74 (100)

126 (100)

 

Grade I

42 (57)

68 (54)

 

Grade II

26 (35)

47 (37)

 

Grade III

5 (7)

10 (8)

 

Grade IV

1 (1)

1 (1)

PPE

Total

379 (100)

2 (100)

 

Grade I

195 (51)

2 (100)

 

Grade II

120 (32)

0 (0)

 

Grade III

62 (16)

0 (0)

 

Grade IV

2 (1)

0 (0)

  1. PLD=pegylated liposomal doxorubicin hydrochloride; PPE=palmar-plantar erythrodysesthesia.